上皮性卵巢癌幸存者的绝经症状:GINECO VIVROVAIRE2研究
该多中心研究纳入166例无复发≥3年的上皮性卵巢癌幸存者,通过妇科咨询、问卷、血样和骨密度检测评估绝经症状。仅4%患者接受激素替代治疗。
要点
- 三分之二幸存者报告性欲下降,手术绝经者下降更明显(P<.02)。
- 有血管舒缩症状的85例中80例未接受激素替代治疗,仅7例(4%)正在使用。
核心结论
- 上皮性卵巢癌幸存者中血管舒缩症状和性功能障碍常见,尤其见于手术绝经者。
- 多数有绝经症状的幸存者可能从激素替代治疗中获益以改善症状。
研究设计与样本
- 多中心研究,纳入166例治疗结束后无复发≥3年的上皮性卵巢癌幸存者。
- 每位患者接受妇科医生咨询,包括血管舒缩症状和性功能问卷、临床检查、血样和骨密度检测。
- 使用经验证问卷测量生活质量、疲劳、失眠和情绪障碍,并与血管舒缩症状进行相关性分析。
主要发现
- 调查时平均年龄62岁(范围21-83岁),III/IV期占48%,治疗结束至调查平均间隔6年。
- 血管舒缩症状与整体生活质量差、疲劳、失眠或情绪障碍无关联。
- 三分之二幸存者报告性欲下降,手术绝经者下降程度大于自然绝经者(P<.02)。
关键数值与推荐
- 85例有血管舒缩症状的患者中,80例在癌症治疗后未接受激素替代治疗。
- 调查时仅7例(4%)患者正在接受激素替代治疗。
临床怎么用
- 对上皮性卵巢癌幸存者应主动评估绝经症状,尤其是手术绝经者的血管舒缩症状和性欲下降。
- 多数有绝经症状的幸存者未接受激素替代治疗,可考虑评估其获益以改善症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We have previously shown that epithelial ovarian cancer (EOC) and its treatments have negative effects on long-term quality of life (QoL) and fatigue. The present multicenter study investigated the main menopausal symptoms and gynecological management of EOC survivors (EOCS). METHODS: 166 patients with relapse-free ≥3 years after the end of treatment attended a consultation with a gynecologist, including a questionnaire related to vasomotor symptoms (VMS) and sexuality, a clinical examination, a blood sample and an osteodensitometry. QoL, fatigue, insomnia and mood disorders were measured with validated questionnaires and correlated to VMS. VMS and QoL were assessed according to natural menopause (NM) or surgical menopause (SM). RESULTS: Mean age at the survey was 62 [21-83] years and stage III/IV (48%). Mean delay since the end of treatment was 6 years. Fifty-nine patients (36%) had SM. Half of patients reported VMS. Seventy-two percent of EOCS with SM had VMS compared to 41% with NM (P < .001). VMS were not associated with poor global QoL, fatigue, insomnia or mood disorders. Two-thirds of EOCS reported a decrease in libido. Patients with SM showed a greater decrease in libido than NM (P < .02). Fourteen percent of them had osteoporosis and 50% osteopenia. Among the 85 patients with VMS, 80 did not receive HRT after cancer treatment. At the time of the survey, only 7 (4%) patients were receiving hormone replacement therapy (HRT). CONCLUSIONS: VMS and sexual disorders are frequently reported by EOCS, particularly among patients with SM. Most EOCS with menopausal symptoms could benefit from HRT to improve these symptoms.
引用
- Gernier F, Gompel A, Rousset-Jablonski C, et al. Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study. Gynecol Oncol. 2021. PMID: 34649724. doi:10.1016/j.ygyno.2021.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。